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Background. This study attempted to longitudinally investigate neuropsychological function, illness representations,
self-esteem, mood and quality of life (QoL) in individuals with chronic fatigue syndrome (CFS) and compared them
with both healthy participants and a clinical comparison group of individuals with autoimmune thyroid disease
(AITD).
Method. Neuropsychological evaluation was administered at two time points, ﬁve weeks apart. Twenty-one
individuals with CFS, 20 individuals with AITD and 21 healthy participants were matched for age, pre-morbid
intelligence, education level and socio-economic status (SES). All groups also completed measures of illness percep-
tions, mood, self-esteem and QoL at both time points.
Results. The CFS group showed signiﬁcantly greater impairment on measures of immediate and delayed memory,
attention and visuo-constructional ability, and reported signiﬁcantly higher levels of anxiety and depression. After
controlling for the eﬀects of mood, the CFS group still demonstrated signiﬁcant impairment in attention. The CFS
group also reported signiﬁcantly lower self-reported QoL than the AITD and healthy participants. In terms of illness
perceptions, the AITD group believed that their condition would last longer, that they had more treatment control
over their condition, and reported less concern than the CFS group.
Conclusions. These results suggest that the primary cognitive impairment in CFS is attention and that this is not
secondary to aﬀective status. The lower treatment control perceptions and greater illness concerns that CFS patients
report may be causally related to their aﬀective status.
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Introduction
Chronic fatigue syndrome (CFS) is a condition charac-
terized by persistent, disabling fatigue lasting for
6 months or more (Fukuda et al. 1994). In addition to
fatigue, individuals with the condition often experi-
ence a combination of chronic and concurrent somatic
symptoms (e.g. headache, sore throat, swollen glands
and myalgia) and a host of cognitive deﬁcits (e.g. im-
paired concentration, attention and memory and
slowed thinking). Prevalence of the condition is esti-
mated at approximately 0.3–0.6% of the population
(Campion et al. 1998) and CFS is most commonly
found in females between the ages of 20 and 40 years
(Pheby, 1999).
A distinct focus of the CFS literature has been cog-
nitive function (Komaroﬀ, 1993 ; Ray et al. 1993 ; Krupp
et al. 1994; DeLuca et al. 1995, 2004 ; Marshall et al.
1997 ; Wearden & Appleby, 1997 ; Christodoulou et al.
1998 ; Michiels et al. 1999 ; Ross et al. 2001 ; Lange et al.
2005). However, variations in methodological ap-
proaches, participant selection criteria and statistical
analyses make direct comparisons between these
studies diﬃcult. Indeed, such methodological vari-
ations may account for the inconsistencies in the re-
search ﬁndings to date. For example, some authors
have highlighted that CFS patients tend to perform
within the normal range on most tests (Grafman et al.
1993 ; Sandman et al. 1993; Cope et al. 1995), others
have reported overall slight impairment (Krupp et al.
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1994; DeLuca et al. 1995), and others have shown that
CFS patients almost always show slowed motor or
cognitive processing abilities (Ray et al. 1993 ; Krupp
et al. 1994 ; DeLuca et al. 1995), and when compared to
healthy controls, CFS patients are more likely to show
neuropsychological impairments in attention, motor
speed, memory and speed of information processing
(Marshall et al. 1997 ; Wearden & Appleby, 1997 ;
Johnson et al. 1998 ; Busichio et al. 2004; DeLuca et al.
2004). It has also been claimed that impairments in
cognitive functioning may be a partial consequence of
aﬀective status (Cope et al. 1995 ; DeLuca et al. 1995 ;
Wearden & Appleby, 1997) ; CFS patients who also
have co-morbid depression show signiﬁcantly poorer
performances on cognitive assessments than their
non-depressed counterparts (Marshall et al. 1997 ;
Wearden & Appleby, 1997).
There is often a disparity between the degree of
subjective complaints of cognitive impairment in CFS
patients and the degree of that cognitive impairment
on neuropsychological examination (Ray et al. 1993 ;
Wood et al. 1994). Explanations for this disparity in-
clude the notion that CFS patients may be able to per-
form well at the time of assessment but this may
ultimately come at the cost of subsequent increased
fatigue (Ray et al. 1993) ; the idea that levels of arousal
and motivation are somewhat diﬀerent in a laboratory
environment to that of everyday life ; and the notion
that patients may exaggerate their reported cognitive
impairment due to depressed mood (Wearden &
Appleby, 1997).
The relationship between CFS and depression is a
complex one. A large proportion of the CFS popu-
lation are depressed (David, 1991 ; Van Hoof et al.
2003) and prevalence rates vary between 50% and
60% (Ax et al. 2001). When comparisons are made to
other chronic illness populations, such as multiple
sclerosis and rheumatoid arthritis (RA), CFS groups
report increased rates of depression (Pepper et al.
1993 ; Wood et al. 1994 ; Johnson et al. 1996). Proposed
explanations for the relationship between CFS and
depression include : (1) major depression (MD) as the
primary cause of CFS; (2) MD as a secondary con-
dition to CFS; and (3) MD and CFS exist as co-morbid
conditions. Again, there are inconsistencies in the
literature. For example, although some researchers
have argued that CFS is an atypical presentation of
primary MD, anxiety or somatization disorder (Katon
et al. 1991 ; Cope et al. 1996 ; Manu et al. 1998 ; van der
Linden et al. 1999 ; Wessely et al. 1999 ; Wessely &
White, 2004), others have proposed that CFS is a dis-
tinct medical illness caused primarily by immune
system dysfunction (Hickie et al. 1990 ; Komaroﬀ &
Buschwald, 1991). CFS patients often claim that cog-
nitive impairment is one of the main factors
contributing to impaired social, relationship and oc-
cupational dysfunction (Abbey & Garﬁnkel, 1990 ;
Ax et al. 2001). This could suggest that depression may
be secondary to CFS (MacDonald et al. 1996; Ax et al.
2001).
Illness perceptions may play a central role in per-
petuating disability levels in CFS (Surawy et al. 1995 ;
Chalder et al. 1999 ; Edwards et al. 2001; Moss-Morris
& Petrie, 2001). More speciﬁcally, catastrophic think-
ing has been found to be related to both disability and
fatigue (Petrie et al. 1995) and aspects of illness beliefs
have been found to predict the progression of CFS (e.g.
increased perceptions of controllability of the con-
dition tend to be linked to a better outcome) (Ray et al.
1997). On the whole, CFS groups have been found to
report increased illness identities, increased percep-
tions of the seriousness of their condition and are more
likely to attribute their condition to immune system
dysfunction than comparison groups (e.g. RA) (Moss-
Morris & Chalder, 2003). These illness beliefs may be
causally related to role and social dysfunction in CFS
(Leventhal et al. 1989 ; Petrie et al. 1995 ; Surawy et al.
1995 ; Ray et al. 1997; Chalder et al. 1999 ; Edwards et al.
2001 ; Moss-Morris & Petrie, 2001; Moss-Morris &
Chalder, 2003).
A further focus of CFS literature to date has been on
quality of life (QoL). Despite inconsistency in deﬁning
QoL and the various domains measured, ﬁndings
have been relatively consistent. For example, both
subjective QoL and health-related QoL have been
found to be low in the CFS population when com-
pared to other groups (Hardt et al. 2001; Rakib et al.
2005). More speciﬁcally, Anderson & Ferrans (1997)
reported that QoL is particularly and uniquely dis-
rupted in CFS whereas Schweitzer et al. (1995) re-
ported that social functioning (in terms of a loss of role
functioning and social isolation) is particularly im-
paired.
Although previous research has played an import-
ant role in raising the proﬁle of CFS, it has been often
been criticized for failing to include an appropriate
clinical comparison group (DeLuca, 1995). In re-
sponse, the present study included a comparison
group of individuals with autoimmune thyroid dis-
ease (AITD) and a healthy control group (matched for
age, and social and educational background). AITD
patients were selected as they share many similar
symptoms to those experienced by CFS patients, par-
ticularly fatigue, low mood and subjective complaints
of cognitive impairment. Findings from objective
neuropsychological assessment in AITD are rarely
reported. Longitudinal research assessing neuro-
psychological functioning in CFS is also rare. This
study, therefore, aimed to compare neuropsychologi-
cal functioning in these two groups in comparison
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with healthy individuals. We also aimed to investigate
the relationship between impairment, illness percep-
tions, mood and QoL to better understand the inter-
play between these domains. Although previous
research has generally investigated cognitive function
cross-sectionally in CFS at one time point, the present
research adopted a repeated-measures design to ex-
plore changes in cognitive functioning over time. This
research is therefore both novel and timely in further-
ing our knowledge of cognitive function in CFS.
Method
CFS participants : sampling and procedure
UK National Health Service (NHS) ethical approval
was sought from the South Glasgow and Clyde Local
Research Ethics Committee, the Lothian Ethics
Committee and from the University of Stirling.
Twenty-one individuals with CFS were recruited by
a lead CFS consultant [then based in the Southern
General Hospital (SGH), Glasgow] (n=16) and
through a CFS support group (n=5). Information let-
ters explicitly detailing the nature of the research and
the participant’s involvement were sent to the lead
CFS consultant (by post) and to the group leader at the
CFS support group (by email). Forty-three letters were
distributed by the SGH and 12 emails were sent by the
CFS support group. The information letters also pro-
vided the ﬁrst author’s contact details. In this way,
only those individuals who elected to take part in the
research were involved. Once the participants had in-
dicated a willingness to participate, the ﬁrst author
contacted them by telephone or email to arrange for
the research to commence. The hospital referrals were
assessed in a private consulting room in the SGH and
the support group patients were assessed at the host
institution.
Participants (11 males and 10 females) were aged
between 18 and 69 years (mean 46.7 years, S.D.=11.58).
Participants’ estimated pre-morbid IQs varied from 97
to 116 (mean 108.1, S.D.=5.06) and they had spent be-
tween 10 and 19 years in full-time education (mean
14.9 years, S.D.=2.72). All participants were from the
central belt of Scotland and had all been diagnosed by
their general practitioner or consultant as having CFS.
All participants fulﬁlled the Centers for Disease
Control (CDC) diagnostic criteria for CFS (Fukuda
et al. 1994). Six (three males and three females) of the
21 participants were taking prescribed medications at
the time of assessment. These medications included
cipralil (10 mg) (n=1) ; prozac (40 mg) (n=2) ; peri-
ndopril (6 mg) (n=1) ; a combination of ﬂuoxetine
(40 mg), trazadone (150 mg), atravent and lorazepam
(1 mg) (n=1) ; and a combination of clonazepam,
baclofen (40 mg) and trimipramine (250 mg) (n=1).
We found no diﬀerences on any of the dependent
variables when we compared the patients taking
medication with the other CFS patients.
AITD participants : sampling and procedure
Twenty-one individuals with conﬁrmed AITD (see
below) who were complaining of symptoms consistent
with hypothyroidism (e.g. tiredness, weight gain and
low mood) but who were clinically euthyroid
(whether taking thyroid supplements or not) were re-
cruited by the lead endocrine consultant in the Royal
Inﬁrmary of Edinburgh (RIE). Appointment letters
were posted to 22 patients with a date for the research
to commence. All but one patient agreed to attend. The
participants were assessed in a private consulting
room in the RIE. One participant subsequently re-
ceived a diagnosis of hypopituitarism and was thus
excluded from the data set. The ﬁnal sample therefore
comprised 20 AITD individuals.
The 20 participants (three males and 17 females)
were aged between 20 and 65 years (mean 43.5 years,
S.D.=13.43). Participants’ estimated pre-morbid IQs
varied from 99 to 116 (mean 110, S.D.=5.44) and they
had spent between 10 and 20 years in education (mean
14.9 years, S.D.=3.29). All participants were from the
east of Scotland and varied in socio-economic status
(SES).
Of the ﬁnal sample, seven individuals (one male, six
females) had Hashimoto’s thyroiditis (HT). The diag-
nosis of HTwas based on the ﬁnding of a typical goitre
in the presence of antibodies directed against thyroid
peroxidase. There were nine patients (one male, eight
females) with spontaneous primary atrophic hypo-
thyroidism (SPAH) and three patients (one male, two
females) in whom thyroid failure developed follow-
ing iodine-131 therapy for hyperthyroidism due to
Grave’s disease (GD). At the time of neuropsycho-
logical testing, all patients were clinically euthyroid
with normal concentrations of serum free thyroxine
and total triiodothyronine. Serum thyroid-stimulating
hormone (TSH) was either normal or suppressed in all
but one patient ; that patient with untreated HT had a
marginally elevated serum TSH of 5.7 mU/l. Finally,
all but two patients were currently taking thyroxine
(ranging from 50 mg to 200 mg daily) at the time of as-
sessment. We found no diﬀerences on any of the de-
pendent variables when we compared the patients
with spontaneous primary atrophic hypothyroidism
versus the other thyroid patients.
Healthy controls : sampling and procedure
Twenty-one lecturers and evening-class students at
a Glasgow Further Education (FE) college were
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recruited. Written permission was sought from the
Assistant Principle at the FE college for the ﬁrst author
to approach students during their evening classes. The
ﬁrst author gave a short presentation to three groups
of students (sports studies, nail care and beauty care)
detailing the nature of the research and explicitly
highlighting what would be expected of the partici-
pants. Willing students were invited to participate that
evening. Lecturers were recruited from the staﬀ-room,
were informed of the nature of the research and their
involvement in it and again were asked to participate.
All willing participants were assessed in a private in-
terviewing room within the college.
Participants were aged between 24 and 57 years
(mean 39.5 years, S.D.=10.64) ; there were six males
and 15 females. Participants were lecturers (n=6)
and students (n=15) and were from the central belt
of Scotland. The participants’ estimated IQs varied
from 102 to 115 (mean 108.1, S.D.=4.05) and they
had spent between 12 and 19 years in education
(mean 14.5 years, S.D.=1.91). All of the participants
varied in socio-economic background. Participants
self-reported as being ‘healthy’ ; they had no medical
complaints, prior or current psychiatric disorder and
were taking no prescribed medications at the time of
assessment.
Measures
All participants were instructed to read a participant
information sheet detailing the nature of the research
and the participant’s involvement. All participants
subsequently signed a consent form and gave basic
demographic details such as age, occupation, number
of years in education and postcode. All participants
then completed the following :
Wechsler Test of Adult Reading (Wechsler, 1981). This test
estimates pre-morbid intellectual functioning and in-
volves presenting the participant with a card showing
50 words. Participants pronounce the words as cor-
rectly as possible. The higher the score, the higher the
participants’ estimated pre-morbid level of intellectual
functioning.
Repeatable Battery for the Assessment of Neuropsychologi-
cal Status (RBANS; Randolph, 2002). Five domains are
assessed: (1) immediate memory; (2) visuospatial/
constructional ability ; (3) language; (4) attention ; and
(5) delayed memory. Tests include list learning
(recall), story memory, ﬁgure copy, line orientation,
picture naming, semantic ﬂuency, digit span, and
coding. The attention domain score is a composite
score based on performance on the digit span and
coding tests. There are two matched, parallel versions
of the RBANS: version A is used at time 1 (T1) and
version B at time 2 (T2). Domain scores have
a standardized mean of 100 and a standard deviation
of 15.
Brief Illness Perception Questionnaire (Broadbent et al.
2006). This measure consists of nine items, eight of
which are based on a Likert scale ranging from 0 to 10.
The eight items include ‘How much does your illness
aﬀect your life? ’ ; ‘How long do you think your illness
will continue?’ ; ‘How much control do you feel you
have over your illness? ’ ; ‘How much do you think
your treatment can help your illness? ’ ; ‘How much
do you experience symptoms from your illness? ’ ;
‘How concerned are you about your illness? ’ ; ‘How
well do you feel you understand your illness? ’ ; and
‘Howmuch does your illness aﬀect you emotionally? ’
The Likert scale indicates perceived severity of illness
experience. For example, ‘How much does your ill-
ness aﬀect your life? ’ (0=no aﬀect at all, 10=severely
aﬀects my life). The greater the score, the more severe
the participant perceives their condition to be. The ﬁ-
nal item asks participants to list in rank order the three
most important factors that they believe caused their
illness. This short, single-item measure was selected to
reduce the measurement load on participants (multi-
item measures tend to be lengthy).
Hospital Anxiety and Depression Scale (HADS; Zigmund
& Snaith, 1983). This is a self-report measure devel-
oped to measure current anxiety and depression in
medical settings. Cut-oﬀ scores are provided for bor-
derline and possibly clinically signiﬁcant scores.
Participants identify how often they experience feel-
ings of depression or anxiety (or both). Fourteen
statements are made such as ‘ I feel tense or wound
up’ and the participant has to rate how often they ex-
perience such feelings (e.g. most of the time through to
not at all). Scores of 0–7 are deﬁned as being within the
normal range, scores of 6–10 within the borderline
range, and scores of o11 are deﬁned as being poten-
tially clinically signiﬁcant. For this sample the coef-
ﬁcient a’s were as follows : anxiety 0.80, depression
0.79, HADS total 0.89.
Rosenberg Self-Esteem Scale (Rosenberg, 1989). This self-
report measures takes a Likert-scale format with 10
statements (e.g. ‘ I feel I have a number of good
qualities ’) answered on a four-point scale. The scale
ranges from ‘strongly agree’ to ‘strongly disagree ’.
The greater the score, the greater the self-esteem an
individual possesses. The score range is therefore be-
tween 0 and 40. For this sample the coeﬃcient a was
0.88.
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World Health Organization Quality of Life Measure – Brief
Form (WHOQoL-BREF; WHO, 1996). This question-
naire comprises 26 questions relating to four speciﬁc
life domains (physical, psychological, social and en-
vironmental). Typical questions include ‘How would
you rate your quality of life? ’ Participants have to rate
each question on a ﬁve-point scale, where 1=very
poor and 5=very good. Domain scores range from 0 to
20. In this sample the coeﬃcient a’s were : physical
0.86, psychological 0.80, social 0.68, environment 0.79.
Patient Generated Index (Ruta et al. 1994). This is an
alternative QoL measure that allows the participant to
choose which areas of their life have been most aﬀec-
ted by their illness. Each participant identiﬁes the ﬁve
most important areas of their life. They are then asked
to score each of the ﬁve important areas with regard to
how badly these areas have been aﬀected by their ill-
ness (0=the worst you could imagine and 10=exactly
as you would like to be). The participants must also
score their general health and non-health-related areas
of their lives on this scale. Finally, the participant is
given 14 ‘ imaginary points ’ that they can spend im-
proving the seven areas of their life. Participants give
the highest number of points to the area they would
like to improve most. For example, they may give all
14 points to one of the seven areas and no points to the
other six areas. Alternatively, they may distribute the
points equally among the seven available areas. The
total score varies from 0 to 100.
The entire procedure was then repeated approxi-
mately 4 to 5 weeks later. Patients with both CFS and
AIFD often report inconsistency in their neuro-
psychological symptoms and, by repeating the as-
sessments at a later date, the authors hoped to increase
the reliability of the data and test consistency of results
over time.
Results
Power calculation and statistical analysis
In this exploratory study we aimed to test for a me-
dium eﬀect size (0.4) with an a set at 0.05 with a power
of 0.80. We carried out a G-power calculation for a
repeated-measures design with group factor (three
levels) and within-subject factor (time) at two levels,
and we based the power calculation on the between-
factors (group) eﬀect. This indicated that we required
a sample size of 22 in each of the three groups. We
tested for main eﬀects of group and grouprtime in-
teractions using 3 (group)r2 (time) analysis of vari-
ance (ANOVA), followed up by Bonferroni post-hoc
comparisons. Categorical data were tested using x2.
Associations between variables were tested using
Pearson’s correlations. All analyses were computed
using SPSS version 16 (SPSS Inc., Chicago, IL, USA).
Description of participants
To test whether the three groups were well matched in
terms of age, IQ and education level, a series of one-
way ANOVAs and x2 comparisons were conducted.
The three groups were well matched in terms of age,
IQ and education but were signiﬁcantly diﬀerent in
terms of gender (x2=7.806, p=0.03). However, gender
was found only to be related to HADS scores, and was
only included as a covariate when analysing between
group diﬀerences in HADS scores. For SES, partici-
pants were graded on the basis of their postcodes
using the ACORN Geodemographic Classiﬁcation
Tool (www.caci.co.uk/acorn/acornmap.asp). Partici-
pants were identiﬁed as being inclusive in one of
ﬁve categories (1=wealthy achievers, 2=urban pros-
perity, 3=comfortably oﬀ, 4=moderate means, 5=
hard pressed). We collapsed sociodemographic cat-
egories 1 and 2 and 4 and 5 and tested for between-
group diﬀerences using x2. No signiﬁcant diﬀerences
were found between the groups for SES (x2=3.070,
p=0.55).
Results of analyses
For the majority of the analyses, no signiﬁcant groupr
time interactions were observed, therefore main eﬀects
(mean scores across the two time points) are pre-
sented.
Neuropsychological status
A series of repeated-measures ANOVAs were con-
ducted (df=2, 59). Signiﬁcant between-group diﬀer-
ences were found between the groups on the domains
of immediate memory, visuo-constructional tasks, at-
tention and delayed memory (see Table 1). Bonferroni
post-hoc analyses showed that the CFS group were
signiﬁcantly more impaired than the healthy partici-
pants on tests of immediate, delayed memory and
visuo-constructional tasks. The CFS group were also
signiﬁcantly more impaired than the AITD group on
tests of attention. Although there were no signiﬁcant
diﬀerences between the groups on the language task,
there was a signiﬁcant grouprtime interaction, the
CFS group improved slightly, the AITD deteriorated
slightly and the healthy participants remained fairly
consistent over time: CFS mean T1=92.5, T2=97.1,
AITD T1=107.0, T2=96.8, controls T1=100.3, T2=
101.3 [F(2, 59)=9.42, p<0.001, gp2=0.24].
In summary, the main result observed was that CFS
patients were consistently more impaired on tests of
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immediate and delayed memory, visuo-constructional
abilities and attention.
Mood
A series of repeated-measures ANOVAs were again
conducted. Signiﬁcant diﬀerences were found be-
tween the groups on measures of anxiety, depression
and self-esteem and the results were consistent over
time. Post-hoc analyses highlighted that the CFS and
AITD groups had signiﬁcantly higher self-reported
levels of depression than the healthy participants. The
CFS group had signiﬁcantly higher levels of anxiety
and lower self-esteem than the healthy participants.
The results of the mood measures are shown in
Table 1.
We then reanalysed the neuropsychological data
controlling for mood. We did this because it is well
established that depressed mood can impair neuro-
psychological performance (Cope et al. 1995 ; Marshall
et al. 1997 ; Wearden & Appleby, 1997). Therefore, the
neuropsychological impairmentwe report above could
be the result of mood, not CFS or AITD. We therefore
computed composite total HADS anxiety/depression
scores by taking an average of the T1 and T2 scores
and entered this composite mood score as a covariate.
When we reanalysed the data, all neuropsychological
between-group diﬀerences were rendered non-
signiﬁcant, with the exception of attention : CFS=91.4
(S.E.=3.6), AITD=103.6 (S.E.=3.5), healthy con-
trols=96.4 (3.7) [F(2, 58)=3.17, p=0.049, gp=0.10,
CFS<AITD]. The eﬀect of time and interaction of
grouprtime was not signiﬁcant. Thus the important
ﬁnding is that, even after controlling for mood, the CFS
group had signiﬁcantly greater impairment in
attention than the AITD clinical comparison group.
Quality of life
Once more, a series of repeated-measures ANOVAs
were conducted. Signiﬁcant diﬀerences were found
between the groups in physical, psychological and
environmental WHOQoL domains, and also on the
Patient Generated Index (PGI) measure. Post-hoc
analyses highlighted that the CFS group had signiﬁ-
cantly lower self-reported QoL in the physical and
psychological QoL domains than both the AITD and
healthy participants. The CFS group also scored lower
on Environment QoL than the AITD group and lower
than the healthy participants on the PGI. The diﬀer-
ences were largely consistent over time, but the CFS
group demonstrated a slight deterioration in physical
QoL between T1 and T2.
Illness perceptions
A series of repeated-measures ANOVAs were run
comparing the illness perceptions of the AITD and
CFS groups. No grouprtime interactions were found
Table 1. Between-group comparisons of neuropsychological status, mood quality of life and self-esteem
CFS AITD Control F p gp
2 Post-hoc
RBANS
Immediate memory 88.8 (2.9) 96.4 (3.1) 104.4 (3.0) 6.77 0.002 0.19 CFS<C
Visuospatial/constructional ability 92.9 (2.7) 95.5 (2.8) 104.1 (2.7) 4.71 0.013 0.14 CFS<C
Language 94.8 (2.1) 101.9 (2.2) 100.8 (2.1) 3.01 0.06 0.09
Attention 89.7 (3.4) 103.1 (3.5) 98.5 (3.4) 4.00 0.023 0.12 CFS<AITD
Delayed memory 87.2 (2.9) 93.5 (3.0) 101.0 (3.0) 5.44 0.007 0.16 CFS<C
AFFECT
HADS Anxiety 10.8 (0.9) 9.8 (0.9) 7.1 (0.9) 4.92 0.01 0.15 CFS>C
HADS Depression 10.4 (0.8) 7.6 (0.9) 3.9 (0.8) 15.5 0.001 0.35 CFS, AITD>C
Self-esteem 15.2 (1.1) 16.8 (1.1) 20.4 (1.1) 5.75 0.005 0.16 CFS<C
WHOQoL
Physical 9.6 (0.5) 12.4 (0.5) 16.1 (0.5) 47.7 0.001 0.62 CFS<AITD<C
Psychological 11.4 (0.5) 12.4 (0.5) 14.6 (0.5) 9.69 0.001 0.25 CFS, AITD<C
Social 12.3 (0.7) 12.6 (0.7) 14.4 (0.7) 3.00 0.06 0.09
Environment 13.3 (0.5) 15.3 (0.5) 14.2 (0.5) 4.39 0.017 0.13 CFS<AITD
PGI 33.1 (3.7) 45.1 (3.8) 56.9 (3.7) 10.61 0.001 0.27 CFS<C
CFS, Chronic fatigue syndrome ; AITD, autoimmune thyroid disease ; C, control group ; RBANS, Repeatable Battery for the
Assessment of Neuropsychological Status ; HADS, Hospital Anxiety and Depression Scale ; WHOQoL, World Health
Organization Quality of Life – Brief Form; PGI, Patient Generated Index.
Values given as mean (standard error).
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but main group eﬀects (df=1, 39) were observed for
timeline [CFS=7.3 (S.E.=0.4), AITD=9.6 (S.E.=0.4),
F=14.8, p=0.001, gp2=0.27], treatment control [CFS=
3.1 (S.E.=0.6), AITD=7.1 (S.E.=0.6), F=23.2, p=0.001,
gp
2=0.37] and concerns [CFS=8.0 (S.E.=0.5), AITD=
6.1 (S.E.=0.5), F=6.82, p=0.013, gp2=0.15]. Thus, the
AITD group believed that their condition would last
longer, that they had greater treatment control over
their condition, and expressed less concern over their
condition compared with the CFS group. We then re-
analysed the illness perception data controlling for
mood using the composite anxiety and depression
scores. The results showed that the AITD group’s
perception of their condition having a longer timeline
and of having more treatment control and concern
was not accountable by mood and remained signiﬁ-
cant.
In terms of attributing cause, the following main
reasons were suggested: ﬂu/virus (CFS=10, AITD=
1), weakened immune system (CFS=2, AITD=0),
stress (CFS=5, AITD=1), genetic cause (CFS=3,
AITD=6), not speciﬁed (CFS=3, AITD=10).
Antibody status
Finally, we conducted a series of correlations to de-
termine the relationship between antibody status in
the AITD group and neuropsychological impairment,
mood and QoL. All correlations proved to be non-
signiﬁcant.
Discussion
This study is the ﬁrst to assess neuropsychological
impairment longitudinally in a group of individuals
with CFS and to use a comparison group of in-
dividuals with AITD, in addition to a healthy control
group.
The ﬁrst main ﬁnding of this study highlighted that
the CFS group were signiﬁcantly more impaired than
the AITD group on attention. This ﬁnding therefore
supports those of other authors who have also pro-
vided objective evidence for poor attention within the
CFS population (McDonald et al. 1993 ; Ray et al. 1993 ;
Sandman et al. 1993 ; Cope et al. 1995 ; Marshall et al.
1997 ; Johnson et al. 1998). The impairment the CFS
group showed in attention was not accounted for by
diﬀerences in mood. This contradicts the ﬁndings of
previous authors who have claimed that cognitive
complaints in CFS are speciﬁcally secondary to de-
pressed or anxious mood (Smith, 1991 ; Grafman et al.
1993 ; McDonald et al. 1993). These results suggest that
the core neuropsychological deﬁcit in CFS is atten-
tional, and that other cognitive deﬁcits that have been
reported may be secondary to this.
Turning to consider QoL, the CFS group reported
lower QoL in the physical and psychological domains
than both the AITD and healthy participants. Poor
QoL has been reported in CFS populations worldwide
(Hardt et al. 2001). Anderson & Ferrans (1997) used a
mixed-method approach to QoL in CFS patients. The
results from the interviews highlighted a devastating
eﬀect on former social relationships, including re-
lationship strain and subsequent loss of relationships.
An inability to engage in social activities, economic
stain, loss of purpose, self-worth, identity and self-
esteem were all consequences of the onset of the con-
dition. Given these qualitative ﬁndings, it is perhaps
not surprising that the CFS group in our study had
lower overall QoL than the AITD group. The AITD
group were receiving treatment for their condition
that helped them to manage the physical symptoma-
tology of their condition. This was not true for the CFS
group, many of whom were receiving no treatment for
the physical symptoms of their condition. Given that
many of the CFS participants were no longer able to
work, many participants reported having to move
house and experienced secondary economic strain. In
addition to chronic fatigue, many members of the CFS
group also reported chronic pain and, as a result,
many experienced diﬃculty in going out. This again
might account for their lower self-reported QoL in the
physical and psychological domains.
We now turn to illness perceptions. In the present
study, the AITD group believed that their condition
would last longer but that they had more treatment
control over their condition, and that they had less
concern regarding their condition than the CFS group.
This is perhaps not surprising given that AITD is a
lifelong condition and the majority of the AITD par-
ticipants were receiving treatment at the time of as-
sessment. Many more participants in the CFS than the
AITD group attributed their conditions to a viral aeti-
ology, thus supporting Moss-Morris & Chalder’s
(2003) ﬁndings (compared to their RA control group,
the CFS group were more likely to attribute cause to a
viral aetiology or immune system dysfunction). The
CFS group were also more likely to consider stress as a
cause, and overall, were more likely than the AITD
group to attribute a cause for their condition (50% of
the AITD group failed to identify a cause). It is striking
that the majority of CFS participants attributed a viral
origin in light of the proposal by Richman et al. (2002)
that Western medicine’s failure to identify a viral
aetiology for CFS has promoted a paradigmatic shift in
research perspectives ; it is possible that this shift un-
derlies the tendency of health professionals to focus on
sociocultural and psychiatric explanations for CFS
(Ware, 1992 ; Cooper, 1997 ; Chaudhuri & Behan, 2004 ;
Dickson et al. 2007). For many CFS patients, this
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increases the risk that people with the condition may
be viewed as being ‘malingerers ’ (Ware, 1992) or as
attempting to escape burdening roles (cf. Parson’s
1951 description of the ‘sick role ’). Given these ﬁnd-
ings, it is perhaps not surprising then that the CFS
participants (1) were keen to attribute cause for their
condition and (2) advocated a physiological aetiology
for that condition.
Edwards et al. (2001) found that individuals with
CFS who had mood disturbance and greater levels of
fatigue also demonstrated more ‘catastrophic think-
ing’. Ray et al. (1992) propose that disturbed mood can
directly aﬀect CFS by exacerbating symptoms and
amplifying the illness experience. We propose the op-
posite may also be true : concern about one’s health (as
found in the present study) may exacerbate CFS
symptomatology and in turn lead to greater anxiety
and depression. More speciﬁcally, patients who are
particularly symptom focused or overly concerned
may use a proportion of their attentional resources
focusing on symptoms, thus making competing com-
plex attentional tasks more diﬃcult. Further research
to clarify the causal direction of the relationship be-
tween symptom focus, aﬀective status and attention is
warranted.
A practical implication of the key ﬁnding of a core
attentional deﬁcit in CFS relates to treatment. It is
likely that CFS patients may have diﬃculty attending
to complex material in cognitive behavioural therapy
(CBT) interventions with an increased likelihood of
forgetting important components. We propose that
such patients would be helped by consolidating ma-
terial using additional handouts or worksheets, for
example.
Limitations
We conclude with a consideration of the limitations of
the current study. First, the CFS participants in this
study may diﬀer from those in other studies in that
they did not have a prior history of aﬀective disorder
or other psychiatric conditions. Second, it is important
to acknowledge that the sample sizes were relatively
small. The voluntary nature of recruitment in both the
CFS and AITD groups will inevitably have introduced
a selection bias. Third, this was a longitudinal study
over a relatively short time-frame and no inferences
can be made regarding the causal nature of neuro-
psychological impairment, mood, QoL and illness
perceptions. Nevertheless, the ﬁndings are important
in identifying, for the ﬁrst time, attention as the key
neuropsychological impairment in CFS, which ap-
pears to remain consistent over time and is not a
consequence of aﬀective status. We propose that other
studies reporting deﬁcits in other areas of cognition in
CFS (e.g. memory, psychomotor function) may reﬂect
a secondary consequence of a core attentional deﬁcit.
Future research should investigate the psychosocial
impact of the attentional impairment and its relation-
ship to mood, illness perceptions, QoL and response to
treatment.
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